Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vicore Pharma Holding acquires INIM Pharma
Mandate

Vicore Pharma Holding acquires INIM Pharma

July 03, 2018 M&A Intellectual Property Capital Markets and Public M&A Life Sciences & Health

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

Related

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

 Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

 Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge has assisted Boliden in the acquisition of the Neves-Corvo and Zinkgruvan mines from Lundin Mining

Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan mine in Sweden. The upfront cash consideration for the entities is USD 1,300 m plus contingent payments that can reach up to USD 150 m, on a cash and debt-free basis. The transaction, that considerably strengthens Boliden's mine production as well as internal zinc and copper concentrate supply, is subject to customary regulatory approvals.
December 10, 2024